Evidence for a selective role of the δ-opioid agonist [8R-(4bS*,8aα,8aβ,12bβ)]7,10-dimethyl-1-methoxy-11-(2-methylpropyl)oxycarbonyl 5,6,7,8,12,12b-hexahydro-(9H)-4,8-methanobenzofuro[3,2-e]pyrrolo[ 2,3-g]isoquinoline hydrochloride (SB-235863) in blocking hyperalgesia associated with inflammatory and neuropathic pain responses

被引:77
作者
Petrillo, P
Angelici, O
Bingham, S
Ficalora, G
Garnier, M
Zaratin, PF
Petrone, G
Pozzi, O
Sbacchi, M
Stean, TO
Upton, N
Dondio, GM
Scheideler, MA
机构
[1] GlaxoSmithKline Pharmaceut, Dept Neurobiol Res, Milan, Italy
[2] GlaxoSmithKline Pharmaceut, Dept Med Chem, Milan, Italy
关键词
D O I
10.1124/jpet.103.055590
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The specific involvement of the delta-opioid receptor in the control of nociception was explored by investigating the pharmacological activity in vivo of a selective, orally active, and centrally penetrant delta-opioid agonist. [8R-(4bS*, 8aalpha, 8abeta, 12bbeta)]7,10-dimethyl-1-methoxy-11-(2-methylpropyl)oxycarbonyl 5,6,7,8,12,12b-hexahydro-(9H)-4,8-methanobenzofuro[3,2-e]pyrrolo[2,3-g]isoquinoline hydrochloride (SB-235863) is a new pyrrolomorphinan with high affinity (K-i = 4.81 +/- 0.39 nM) for the delta-opioid receptor, full agonist activity, and binding selectivity versus the mu- and kappa-opioid receptors of 189-fold and 52-fold, respectively. Perorally administered SB-236863 was inactive in the rat tail-flick and hot-plate tests of acute pain response, but potently reversed thermal hyperalgesia in rats resulting from a carrageenan-induced inflammatory response. This activity could be blocked by the delta-opioid antagonist naltrindole (3 mg/kg s.c.), but selective mu- and kappa-opioid antagonists were ineffective. Naltrindole (1 mug i.c.v.) also blocked the activity of 10 mg/kg (p.o.) SB-235863, showing that the compound activates delta-opioid receptor sites in the central nervous system. SB-235863 was additionally effective at reversing chronic hyperalgesia in the Seltzer rat model of partial sciatic nerve ligation after peroral administration. These data show that the delta-opioid receptor plays a selective role in regulating evoked and lasting changes in nociceptive pain signaling. Classical side effects of mu- and kappa-opioid receptor activation (slowing of gastrointestinal transit and motor incoordination, respectively) were not observed after administration of 70 mg/kg (p.o.) SB-235863, nor was evoked seizure activity affected. These results suggest a selective and limited role of delta-opioid receptors in the modulation of nociception.
引用
收藏
页码:1079 / 1089
页数:11
相关论文
共 39 条
[1]  
BILSKY EJ, 1995, J PHARMACOL EXP THER, V273, P359
[2]  
Brandt MR, 2001, J PHARMACOL EXP THER, V296, P939
[3]  
Brooks DP, 1997, J PHARMACOL EXP THER, V280, P1176
[4]   Up-regulation and trafficking of δ opioid receptor in a model of chronic inflammation:: implications for pain control [J].
Cahill, CM ;
Morinville, A ;
Hoffert, C ;
O'Donnell, D ;
Beaudet, A .
PAIN, 2003, 101 (1-2) :199-208
[5]  
CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099
[6]   SPINAL MU-OPIOID AND DELTA-OPIOID, BUT NOT KAPPA-OPIOID-RECEPTOR AGONISTS ATTENUATE RESPONSES TO NOXIOUS COLORECTAL DISTENSION IN THE RAT [J].
DANZEBRINK, RM ;
GREEN, SA ;
GEBHART, GF .
PAIN, 1995, 63 (01) :39-47
[7]   Patterns of quantitative sensation testing of hypoesthesia and hyperalgesia are predictive of diabetic polyneuropathy - A study of three cohorts [J].
Dyck, PJ ;
Dyck, PJB ;
Velosa, JA ;
Larson, TS ;
O'Brien, PC .
DIABETES CARE, 2000, 23 (04) :510-517
[8]   Measurement of responses from Gi-, Gs-, or Gq-coupled receptors by a multiple response element/cAMP response element-directed reporter assay [J].
Fitzgerald, LR ;
Mannan, IJ ;
Dytko, GM ;
Wu, HL ;
Nambi, P .
ANALYTICAL BIOCHEMISTRY, 1999, 275 (01) :54-61
[9]   DISSOCIATION OF ANTINOCICEPTIVE AND MOTOR EFFECTS OF SUPRASPINAL OPIOID AGONISTS IN THE RAT [J].
FRANCK, LS ;
MIASKOWSKI, C ;
PUTRIS, J ;
LEVINE, JD .
BRAIN RESEARCH, 1991, 563 (1-2) :123-126
[10]   Antihyperalgesic effects of δ opioid agonists in a rat model of chronic inflammation [J].
Fraser, GL ;
Gaudreau, GA ;
Clarke, PBS ;
Ménard, DP ;
Perkins, MN .
BRITISH JOURNAL OF PHARMACOLOGY, 2000, 129 (08) :1668-1672